- 1. D-His-6-Pro-8-NEt-LHRH
- [LH-RH. A hormone that stimulates the production of sex hormones in men and women. ( NCI )] (UMLS (NCI) C0023610) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Neuroreactive Substance or Biogenic Amine; Hormone =[HS400] GONADOTROPINS;
Hypothalamic Hormone;
neuropeptide;
oligopeptide =6-D-(2-naphthyl)alanyl-GnRH;
ganirelix;
6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig);
6-[O-(1,1-Dimethylethyl)-D-serine]-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) 2-(aminocarbonyl)hydrazide;
GONADORELIN ACETATE;
GONADORELIN HYDROCHLORIDE;
GONADORELIN ACETATE;
GONADORELIN HYDROCHLORIDE;
| - 21. DHAD/PRED/VCR/VP-16
- (UMLS (NCI) C0281404) =Therapeutic or Preventive Procedure ;
|
- 2. DHA-Paclitaxel
- [A combination of DHA (a natural fatty acid) and paclitaxel (an anticancer drug) that is being studied as a treatment for cancer. ( NCI )] (UMLS (NCI) C1134470) Docosahexaenoic Acid-Paclitaxel conjugate;
TXP =Organic Chemical; Pharmacologic Substance ;
| - 22. DHAD/PSC 833/VP-16
- (UMLS (NCI) C0281726) =Therapeutic or Preventive Procedure
|
- 3. DHA-Paclitaxel/Gemcitabine
- (UMLS (NCI) C1327871) =Therapeutic or Preventive Procedure ;
| - 23. DHAD/TAX
- (UMLS (NCI) C0281593) =Therapeutic or Preventive Procedure
|
- 4. DHAC
- [A synthetic nucleoside analogue of deoxycytidine. Dihydro-5-azacytidine inhibits DNA methyltransferase, thereby interfering with abnormal DNA methylation patterns that are associated with genetic instability in some tumor cells. Inhibition of this enzyme may restore expression of tumor-suppressor genes and result in antitumor activity. (NCI04) ( NCI )] (UMLS (NCI) C0048906) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
| - 24. DHAD/TAX/TSPA
- (UMLS (NCI) C0281473) =Therapeutic or Preventive Procedure
|
- 5. DHAD/5-FU/MTX
- (UMLS (NCI) C0083765) =Therapeutic or Preventive Procedure ;
| - 25. DHAD/TOPO/TSPA
- (UMLS (NCI) C0678042) =Therapeutic or Preventive Procedure ;
|
- 6. DHAD/FAMP
- (UMLS (NCI) C0281747) =Therapeutic or Preventive Procedure
| - 26. DHAD/TSPA
- (UMLS (NCI) C0280683) =Therapeutic or Preventive Procedure
|
- 7. DHAD/GM-CSF
- (UMLS (NCI) C0279103) =Therapeutic or Preventive Procedure
| - 27. DHAD/TSPA/VP-16
- (UMLS (NCI) C0280523) =Therapeutic or Preventive Procedure
|
- 8. DHAD/GM-CSF/VP-16
- (UMLS (NCI) C0281674) =Therapeutic or Preventive Procedure
| - 28. DHAD/VNB
- (UMLS (NCI) C0677974) =Therapeutic or Preventive Procedure
|
- 9. DHAD/HC
- (UMLS (NCI) C0281308) =Therapeutic or Preventive Procedure ;
| - 29. DHAD/VP-16
- (UMLS (NCI) C0279049) =Therapeutic or Preventive Procedure
|
- 10. DHAD/IFF
- (UMLS (NCI) C0280505) =Therapeutic or Preventive Procedure ;
| - 30. DHE
- [The purified component of HEMATOPORPHYRIN DERIVATIVE, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (HEMATOPORPHYRIN PHOTORADIATION); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of PHOTODYNAMIC THERAPY in the United States. ( MSH )] (UMLS (NCI) C0058031) =Organic Chemical; Pharmacologic Substance ;
|
- 11. DHAD/IFF/mesna
- (UMLS (NCI) C0393048) =Therapeutic or Preventive Procedure
| - 31. DHE/OMEP
- (UMLS (NCI) C0678018) =Therapeutic or Preventive Procedure
|
- 12. DHAD/IFF/mesna/VP-16
- (UMLS (NCI) C0338297) =Therapeutic or Preventive Procedure
| - 32. DHEA Analog 8354
- (UMLS (NCI) C0539514) =Steroid; Pharmacologic Substance ;
|
- 13. DHAD/IFF/VP-16
- (UMLS (NCI) C0280689) =Therapeutic or Preventive Procedure
| - 33. Dhegiha
- (UMLS (HL7) C1699696) =Language =MississippiValley;
=Osage;
Omaha-Ponca;
Kansa;
Alkansea;
|
- 14. DHAD/IFN-A
- (UMLS (NCI) C0338108) =Therapeutic or Preventive Procedure ;
| - 34. DHFR
- [Dihydrofolate reductase converts dihydrofolate into tetrahydrofolate, a methyl group shuttle required for the de novo synthesis of purines, thymidylic acid, and certain amino acids. It is a drug target. Variation in gene expression or sequence may alter the efficacy of chemotherapy. (from LocusLink and NCI) ( NCI )] (UMLS (NCI) C0039667) =Amino Acid, Peptide, or Protein; Enzyme ;
=amine oxidoreductase;
Genes, Reporter |
- 15. DHAD/L-ATRA/VP-16
- (UMLS (NCI) C0338224) =Therapeutic or Preventive Procedure
| - 35. DHFR
- [This gene is involved in biosynthesis, nucleotide metabolism and the immune response. ( NCI )] (UMLS (NCI) C1333216) DHFR Gene;
Dihydrofolate Reductase Gene =Gene or Genome ;
|
- 16. DHAD/L-PAM
- (UMLS (NCI) C0392932) =Therapeutic or Preventive Procedure ;
| - 36. DHFR Inhibitor
- [Substances that inhibit Dihydrofolate Reductase interfering with the conversion of Dihydrofolate to Tetrahydrofolate, causing inhibition of nucleotide biosynthesis and protein synthesis. ( NCI )] (UMLS (NCI) C1373048) Dihydrofolate Reductase Inhibitor;
Dihydrofolate Reductase Inhibitors;
=Pharmacologic Substance ;
=antifolate;
|
- 17. DHAD/MGBG/VBL/VP-16
- (UMLS (NCI) C0280467) =Therapeutic or Preventive Procedure
| - 37. DHODH
- [This gene plays a role in pyrimidine metabolism. ( NCI )] (UMLS (NCI) C1333217) DHODH Gene;
Dihydroorotate Dehydrogenase Gene =Gene or Genome ;
|
- 18. DHAD/PCB/PRED/VCR
- (UMLS (NCI) C0255600) =Therapeutic or Preventive Procedure
| - 38. Dhori virus
- [ ] (UMLS (CSP) C0206549) =Virus
|
- 19. DHAD/PM/VP-16
- (UMLS (NCI) C0279110) =Therapeutic or Preventive Procedure
| - 39. DHP
- [partially saturated derivative of pyridine; binds to and inhibits the voltage-gated calcium channel of skeletal muscle T junctional membranes, the principle molecular transducer of excitation-contraction coupling. ( CSP )] (UMLS (CSP) C0220821) =Organic Chemical; Pharmacologic Substance ;
=[CV200] CALCIUM CHANNEL BLOCKERS;
pyridine |
- 20. DHAD/PRED
- (UMLS (NCI) C0678009) =Therapeutic or Preventive Procedure
| - 40. DHPG sodium
- [The sodium salt form of ganciclovir, a synthetic, antiviral, purine nucleoside analog with antiviral activity, especially against cytomegalovirus (CMV). Ganciclovir sodium is a prodrug that is phosphorylated and subsequently converted into its triphosphate form, the active metabolite ganciclovir-5-triphosphate (ganciclovir-TP), in the infected cells by cellular kinases. Ganciclovir-TP competes as a substrate with nucleotide triphosphates for viral DNA polymerase. Once it gets incorporated into DNA strand, it prevents further polymerization of DNA, thereby interfering with viral DNA replication. ( NCI )] (UMLS (NCI) C0282399) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
=2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one;
=GANCICLOVIR (AS SODIUM) 500;
GANCICLOVIR (AS SODIUM) 250 MG |
home
